Mar 15, 2022 / 03:15PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everybody. I'm Luke Sergott from Life Science Tools Diagnostics here at Barclays. With me, it's a pleasure to have Roland Sackers and John Gilardi of QIAGEN. It's been a long time, good to see you in person. So with that, if you guys want to open with a little comments, then we can dig in.
Roland Sackers - QIAGEN N.V. - CFO, MD & Member of Management Board
Yes, why not. And again, thanks for having us and also for us, I think the first physical conference, at least in the U.S. for quite some while. It's good to be back. I thought (inaudible) but again. Yes, I think it's good to be -- and also good to report out on some of the developments we see. And as you know, we put out a very good fiscal year '21, clearly had a strong performance, actually both overall, what we call COVID-related business, which I think is probably more important for us also very strong performance of the non-COVID side, we have seen now, I think, consecutive quarters where we were able not only
Qiagen NV at Barclays Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot